Thanks to Tim W. for the opportunity to share our story. Unlike most small-caps, we've built Daxor on fiscal discipline and patience. Our blood volume technology, #BVA, is poised for breakthrough growth with FDA clearance of our next-gen analyzer on the horizon. What we've created is rare: life-saving medical innovation paired with responsible management. Michael Feldschuh #MedTech #ValueInvesting #ImpactStock #PatientCare #DXR
CEO @ Alpha Wolf Capital Helping the"Hidden Gems" of small and microcap companies with strong leadership teams, game-changing services, or products needed to improve the world.
$DRX is an under-the-radar play coming to an inflection point soon. With his background on Wall Street, Michael has given him a leg up on most small and microcap companies; he took a slower path, built a foundation of strength across the board, and positioned Daxor for long-term success. You can imagine this for a moment. This company was listed in the public markets in 1971, with 4.5 million shares. Unlike the companies that list today and become perpetual capital raisers by issuing more shares and diluting existing shareholders, this company only has 4.9 million outstanding shares. After 54 years on the exchange, they kept their cap table immaculate. Every small and microcap company could learn some incredibly valuable lessons from Michael. This story is going to get much more interesting shortly. Please keep it on your radar.